CEO Elisabet de los Pinos was paid $3,956,167 in fiscal year 2025, ↑ up 9.8% from fiscal year 2024 (SEC filing 0001193125-26-163933 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,956,167 ↑ Elisabet de los Pinos total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AURA's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Elisabet de los Pinos | $645,483 | $0 | $1,492,378 | $1,513,293 | $284,013 | $0 | $21,000 | $3,956,167 |
| President, Chief Executive Officer and Director | ||||||||
| Anthony Gibney | 345,909 | 0 | 1,006,915 | 1,209,402 | 189,000 | 0 | 0 | 2,751,226 |
| Chief Financial and Business Officer | ||||||||
| J. Jill Hopkins | 551,250 | 0 | 926,477 | 469,738 | 220,500 | 0 | 21,000 | 2,188,965 |
| Chief Medical Officer and President of Research and Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Elisabet de los Pinos | $3,956,167 | $3,604,339 | $4,044,598 | ↑ +351,828 |
| Anthony Gibney | 2,751,226 | — | — | — |
| J. Jill Hopkins | 2,188,965 | 1,226,076 | 2,935,681 | ↑ +962,889 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Aura Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AURA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses AURA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AURA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Antony Mattessich | Independent Director | $214,891 |
| David Johnson | Chair of the Board | $235,331 |
| Giovanni Mariggi, Ph.D | Independent Director | — |
| Karan Takhar | Independent Director | — |
| Sapna Srivastava, Ph.D | Independent Director | $213,271 |
| Teresa Marie Bitetti | Independent Director | $283,562 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | Greater-than-10% holder | 2026-05-07 | D | 6,922,870 | $6 | $39,044,987 | Common, indirect | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 553,844 | 0 | 0 | Common | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 2,169,103 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 600,118 | 0 | 0 | Common | Form 4 ↗ |
| Antony Mattessich | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Antony Mattessich | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| David Johnson | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Johnson | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Teresa Marie Bitetti | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Teresa Marie Bitetti | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Anthony Gibney | See Remarks | 2026-06-16 | D | 12,824 | 6 | 82,330 | Common | Form 4 ↗ |
| Conor Kilroy | See Remarks | 2026-07-01 | A | 14,858 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-07-07 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-07-07 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Susan Abu-Absi | Chief Operating Officer | 2026-09-01 | A | 134,513 | 0 | 0 | Common | Form 4 ↗ |
| Susan Abu-Absi | Chief Operating Officer | 2026-09-01 | A | 265,487 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy Elazzouzi | SVP, Finance & PAO | 2026-09-01 | A | 46,460 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy Elazzouzi | SVP, Finance & PAO | 2026-09-01 | A | 23,540 | 0 | 0 | Common | Form 4 ↗ |
| J. Jill Hopkins | Chief Medical Officer | 2026-09-01 | A | 116,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Jill Hopkins | Chief Medical Officer | 2026-09-01 | A | 58,850 | 0 | 0 | Common | Form 4 ↗ |
| Erica Kratz | Chief Reg. & Quality Officer | 2026-09-01 | A | 199,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erica Kratz | Chief Reg. & Quality Officer | 2026-09-01 | A | 100,885 | 0 | 0 | Common | Form 4 ↗ |
| Julie Person | Chief People Officer | 2026-09-01 | A | 107,611 | 0 | 0 | Common | Form 4 ↗ |
| Julie Person | Chief People Officer | 2026-09-01 | A | 212,389 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Elisabet de los Pinos | RSU | — | — | — | — | — | $1,492,378 |
| Anthony Gibney | OPTION | — | — | — | — | — | 1,209,402 |
| Elisabet de los Pinos | OPTION | — | — | — | — | — | 1,513,293 |
| Anthony Gibney | RSU | — | — | — | — | — | 1,006,915 |
| J. Jill Hopkins | RSU | — | — | — | — | — | 926,477 |
| J. Jill Hopkins | OPTION | — | — | — | — | — | 469,738 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Elisabet de los Pinos | $1,492,378 | $0 | $1,513,293 | 0.0% |
| Anthony Gibney | 1,006,915 | 0 | 1,209,402 | 0.0% |
| J. Jill Hopkins | 926,477 | 0 | 469,738 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| J. Jill Hopkins | RSU | 67,500 | — | $367,875 |
| Elisabet de los Pinos | RSU | 60,937 | — | 332,107 |
| J. Jill Hopkins | Option | 91,667 | 8.97 | — |
| Elisabet de los Pinos | Option | 128,410 | 7.77 | — |
| Elisabet de los Pinos | Option | 255,680 | 7.68 | — |
| Elisabet de los Pinos | RSU | 122,201 | — | 665,995 |
| Elisabet de los Pinos | Option | 50,782 | 10.18 | — |
| Elisabet de los Pinos | RSU | 194,320 | — | 1,059,044 |
| J. Jill Hopkins | RSU | 120,635 | — | 657,461 |
| Anthony Gibney | Option | 250,000 | 6.16 | — |
| J. Jill Hopkins | Option | 79,365 | 7.68 | — |
| J. Jill Hopkins | Option | 22,471 | 7.77 | — |
| J. Jill Hopkins | RSU | 21,386 | — | 116,554 |
| Anthony Gibney | RSU | 150,000 | — | 817,500 |
We target a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus or long-term incentives.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-08-05 | — | — | — | — | — |
| 2025 | 2025-06-17 | — | — | — | — | — |
| 2024 | 2024-06-20 | — | — | — | — | — |
| 2023 | 2023-06-07 | — | — | — | — | — |
| 2022 | 2022-06-15 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-08-05 | —a |
| 2025 | 2025-06-17 | —b |
| 2024 | 2024-06-20 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Teresa Marie BitettiIndependent · Compensation · Newly elected | $34,436 | $123,060 | $126,066 | $0 | $0 | $283,562 |
| David JohnsonIndependent · Board Chair · Nominating/Governance | 77,060 | 80,340 | 77,931 | 0 | 0 | 235,331 |
| Antony MattessichIndependent · Audit · Nominating/Governance (Chair) | 56,620 | 80,340 | 77,931 | 0 | 0 | 214,891 |
| Sapna Srivastava, Ph.DIndependent · Audit (Chair) | 55,000 | 80,340 | 77,931 | 0 | 0 | 213,271 |
| Elisabet de los Pinos, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Giovanni Mariggi, Ph.DIndependent · Audit · Compensation (Chair) | 0 | 0 | 0 | 0 | 0 | 0 |
| Karan TakharIndependent · Compensation · Nominating/Governance · Not standing for re-election | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $223,116 |
| Equity awards (grant-date value) | $364,080 |
| All other compensation | $0 |
| Total cost of the board | $587,196 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aura Biosciences | 2025 | Elisabet de los Pinos | $645,483 | $1,492,378 | $1,513,293 | $284,013 | $3,956,167 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Elisabet de los Pinos | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
| 2 | Section 01, Anthony Gibney | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 2,751,226. Filing ↗machine: r4 · c28 · span 502083–502092 |
| 3 | Section 01, J. Jill Hopkins | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 2,188,965. Filing ↗machine: r5 · c29 · span 513138–513147 |
| 4 | Section 03, Elisabet de los Pinos RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r2 · c13 · span 474616–474625 |
| 5 | Section 03, Anthony Gibney OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r4 · c17 · span 497932–497941 |
| 6 | Section 03, Elisabet de los Pinos OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r2 · c17 · span 476001–476010 |
| 7 | Section 03, Anthony Gibney RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r4 · c13 · span 496547–496556 |
| 8 | Section 03, J. Jill Hopkins RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r5 · c13 · span 507607–507614 |
| 9 | Section 03, J. Jill Hopkins OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r5 · c17 · span 508990–508997 |
| 10 | Section 07, pay ratio | 10-K | 2026-03-30 | 0001193125-26-130401 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Teresa Marie Bitetti | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 283,562. Filing ↗machine: t6 · r2 · c15 · span 330035–330244 |
| 12 | Section 08, David Johnson | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 235,331. Filing ↗machine: t6 · r3 · c15 · span 336070–336279 |
| 13 | Section 08, Antony Mattessich | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 214,891. Filing ↗machine: t6 · r5 · c15 · span 348345–348554 |
| 14 | Section 08, Sapna Srivastava, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 213,271. Filing ↗machine: t6 · r6 · c15 · span 354390–354599 |
| 15 | Section 08, Elisabet de los Pinos, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Giovanni Mariggi, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t6 · r4 · c11 · span 340919–340920 |
| 17 | Section 08, Karan Takhar | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t6 · r7 · c11 · span 359228–359229 |
| 18 | Section 02, Matrix Capital Management Company, LP 2026-05-07 | Form 4 | 2026-05-11 | 0000950142-26-001346 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Antony Mattessich 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Antony Mattessich 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, David Johnson 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, David Johnson 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Sapna Srivastava 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Sapna Srivastava 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Teresa Marie Bitetti 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Teresa Marie Bitetti 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Anthony Gibney 2026-06-16 | Form 4 | 2026-06-16 | 0001193125-26-272703 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Conor Kilroy 2026-07-01 | Form 4 | 2026-07-01 | 0001193125-26-292685 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jeremy Bender 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Jeremy Bender 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Susan Abu-Absi 2026-09-01 | Form 4 | 2026-09-01 | 0002148701-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Susan Abu-Absi 2026-09-01 | Form 4 | 2026-09-01 | 0002148701-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Amy Elazzouzi 2026-09-01 | Form 4 | 2026-09-01 | 0002042910-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Amy Elazzouzi 2026-09-01 | Form 4 | 2026-09-01 | 0002042910-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, J. Jill Hopkins 2026-09-01 | Form 4 | 2026-09-01 | 0001997710-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, J. Jill Hopkins 2026-09-01 | Form 4 | 2026-09-01 | 0001997710-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Erica Kratz 2026-09-01 | Form 4 | 2026-09-01 | 0002148785-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Erica Kratz 2026-09-01 | Form 4 | 2026-09-01 | 0002148785-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Julie Person 2026-09-01 | Form 4 | 2026-09-01 | 0001946505-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Julie Person 2026-09-01 | Form 4 | 2026-09-01 | 0001946505-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 06, 2026 vote | Form 8-K | 2026-08-05 | 0001193125-26-335157 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 45 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0000950170-25-087885 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 46 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0001193125-24-165656 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 47 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 48 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 49 | Section 09b board cost (computed) | Computed | — | — | Cash 223,116 + equity 364,080 + all other 0 = 587,196, summed across the director compensation table rows.machine: formula: Σ = 587,196 |
| 50 | Aura Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163933 | CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.